Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT00640523 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT00640523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00640523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
November 30, 2011
Enrollment
23 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)